Although vitamin K antagonists (VKAs) are highly effective in the prevention and treatment of thromboembolic events, they have limitations related to drug and food interactions. VKAs … See more With a total cohort of 321 501 OAC-naive patients with NVAF, NAXOS is among the largest observational studies to assess the use and effects of OACs, and it offers a nationwide … See more Because of their sensitive nature, the data are available only to investigators habilitated by the French National Health System. Patient consent was not required for this study (not … See more In NAXOS, apixaban-treated patients had a lower risk of major bleeding events leading to hospitalization, lower risk of stroke and STEs, … See more WebWhat are the future directions? Head-to-head compari-sons of DOACs in randomized clinical trials are unlikely; therefore, prospective, large-scale observational studies (such as ongoing, prospective global registries in AF)20 are expected to further expand the evidence on existing drug choices and inform in more detail specific differences ...
AnticoagEvaluator - American College of Cardiology
WebJun 10, 2024 · DOACs: Finally a Head-to-Head Comparison. Today there is clinical data comparing the DOACs against each other. (And support my original reports.) A comprehensive review of 36 randomized control … WebAug 1, 2024 · Indirect comparisons and retrospective cohort studies suggest that apixaban may be associated with a lower risk of major bleeding than other DOACs, but there are no head-to-head trials with DOACs. Therefore, current guidelines do not recommend one DOAC over another and the choice of a specific DOAC is mainly based on physician and … resound 561
The comparative effectiveness of direct oral anti-coagulants and …
WebNov 4, 2024 · In 2024, andexanet alfa was approved to reverse factor Xa inhibitors (FXaI). 13 While the safety data from these landmark trials were promising, head-to-head trials have not compared the safety and … WebMay 26, 2024 · Nowadays, data from larger head-to-head trials comparing DOACs with LMWH in cancer-associated VTE are available. The SELECT-D trial for rivaroxaban, the … prototype steamdb